DMS 79Homo sapiens (Human)Cancer cell line

Also known as: Darmouth Medical School 79, DMS79, DMS-79, DMS76 (In text of PubMed 20439192.)

🤖 AI SummaryBased on 14 publications

Quick Overview

Human small cell lung cancer cell line with known genetic and molecular characteristics.

Detailed Summary

DMS 79 is a human small cell lung cancer (SCLC) cell line derived from a tumor, commonly used in cancer research. It has been extensively studied for its genetic and molecular profiles, including mutations and gene expression patterns. Research on DMS 79 has contributed to understanding the mechanisms of cancer progression and drug resistance. This cell line is particularly noted for its role in studies involving the epidermal growth factor receptor (EGFR) and its implications in cancer metastasis. Additionally, DMS 79 has been utilized in investigations related to the effects of various therapeutic agents and their efficacy in targeting specific pathways within SCLC. The cell line's characteristics make it a valuable tool for studying the biological behavior of SCLC and developing targeted therapies.

Research Applications

Cancer biologyDrug developmentGenetic and molecular profilingTherapeutic target identification

Key Characteristics

EGFR expressionSmall cell lung cancer originMetastasis researchDrug resistance studies
Generated on 6/16/2025

Basic Information

Database IDCVCL_1178
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age65
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeATCC
Source IDACH-000703_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg280Glufs*65 (c.837delG) (p.G279fs)Unspecified-Unknown
MutationSimpleRB1p.Gly801Ter (c.2401G>T)Homozygous-Unknown, Unknown
MutationSimplePTPRUp.Glu442Ter (c.1324G>T)Heterozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10
D13S317
11
D16S539
12
D18S51
14,17
D19S433
13.2,15
D21S11
30
D2S1338
17,25
D3S1358
18
D5S818
10
D7S820
9,11
D8S1179
12,14
FGA
21
Penta D
11,13
Penta E
7
TH01
8
TPOX
8
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Sauter G., Lesniewski R., Semizarov D.

Mol. Cancer Res. 5:331-339(2007).

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

Nakagawa K., Nomura H., Ishikawa Y.

Lancet 363:775-781(2004).

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.

Hansen L.T., Lundin C., Spang-Thomsen M., Petersen L.N., Helleday T.

Int. J. Cancer 105:472-479(2003).

In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.

Poulsen H.S.

Br. J. Cancer 78:631-640(1998).

Glucocorticoid inhibition of ACTH peptides: small cell lung cancer cell lines are more resistant than pituitary corticotroph adenoma cells.

White A.

J. Mol. Endocrinol. 10:25-32(1993).

Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung.

Noll W.W., Cate C.C., Maurer L.H.

Cancer 45:906-918(1980).

Growth characteristics and heterogeneity of small cell carcinoma of the lung.

Vindelov L.L., Hansen H.H., Spang-Thomsen M.

Recent Results Cancer Res. 97:47-54(1985).